Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

1.600 -0.570 (-26.27%)
Streaming Delayed Price Updated: 11:17 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma’s Advancing Clinical Mission to Better Treat Eye Disease Sends Shares 89% Higher Since August ($OKYO)
Via AB Newswire
News headline image
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited Announces Withdrawal of Public Offering
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited Announces Withdrawal of Public Offering
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
Webull’s community of active participants can now access OKYO's profile on the leading mobile-first brokerage platform 
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited
Via ACCESSWIRE
News headline image
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
From OKYO Pharma LTD
Via GlobeNewswire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Via ACCESSWIRE
News headline image
Notice of General Meeting and Publication of Circular
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Notice of Intention to Delist From The London Stock Exchange
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
By David Willey, Benzinga 
Via TheNewswire.com
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.